(Reuters) – Pfizer Inc (NYSE:) and BioNTech SE (NASDAQ:) on Tuesday asked U.S. health regulators to authorize their COVID-19 vaccine in kids aged 5 to 11.
According to data from American Academy of Pediatrics, COVID-19 infection rates have increased in children and reached their peak in September. The U.S. Food and Drug Administration has been asked to approve the application.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.